- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Sygnature Discovery Announces Research Partnership with Daewoong Pharma
The partnership will allow Sygnature Discovery to provide virtual high throughput screening expertise, among other services, to Daewoong Pharma's projects.
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.
Sygnature Discovery will provide integrated drug discovery support using specialist fragment-based drug discovery (FBDD) and virtual high throughput screening (vHTS) expertise from its medicinal chemistry, biology, and computational science teams. The company will also support protein science and crystallography to accelerate novel drug discovery for Daewoong’s project.
Read more about this story here.
